Navigation Links
Eclipsys Sunrise Acute Care Receives CCHIT Certification
Date:11/5/2007

lable standards, and comparing certification processes in other industries and other countries. The inspection process is based on real-life medical scenarios designed to test products rigorously against the clinical needs of providers and the quality and safety needs of healthcare consumers and payers. One script, for example, recreates a scenario of a middle-aged man admitted through the emergency department after sustaining fractures in an automobile accident. The script tests the ability of the EHR to provide clinical decision support during the ordering and administration of medications, and to track whether laboratory and radiology orders have been entered and received.

About Eclipsys

Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and access management software, clinical content and professional services that help healthcare organizations improve clinical, financial, operational and client satisfaction outcomes. For more information, see http://www.eclipsys.com or email info@eclipsys.com.

About CCHIT

The Certification Commission for Healthcare Information Technology (CCHIT(sm)) is an independent, nonprofit organization that has been named by the federal government as the Recognized Certification Body for health information technology. Its mission is to accelerate the adoption of health information technology by creating a credible, sustainable certification program. The certification requirements are based on widely accepted industry standards and involve the work of hundreds of expert volunteers and input from a variety of stakeholders throughout the health care industry. More information on CCHIT and CCHIT Certified(sm) products is available at http://www.cchit.org.

Statements in this news release concerning the benefits that may be provided Eclipsys software o
'/>"/>

SOURCE Eclipsys Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Eclipsys Knowledge-Based Charting Helps Health First Improve Patient-Care Outcomes
2. Eclipsys User Network Brings Eclipsys Clients Together to Share Outcome Improvement Strategies
3. SingHealth Selects Eclipsys Solutions to Help Improve Clinical Outcomes, First Sunrise Clinical Manager Client Outside of North America
4. Eclipsys Announces Relocation of Corporate Headquarters to Atlanta, GA
5. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
6. Sunrise Settles Litigation Regarding Its 2007 Annual Meeting
7. Diabetes appears to increase risk of death for patients with acute coronary syndromes
8. Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility
9. Study shows insurance status, not race, linked to complications in patients with acute appendicitis
10. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
11. Acute lung injury patients one-third less likely to die in closed model ICUs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...July 24 /PRNewswire-USNewswire/ -- Steven Mosher,...I), says that America has,a hidden problem of sex ...feminists refuse to address., In PRI,s latest You...,East and South Asian countries, of sex-selective ...actice has already claimed the lives of over 100,m...
(Date:7/24/2008)...July 24 /PRNewswire/ -- A new alliance of animal,l...roblems -- obesity -- in,pets and pet owners., Am...ne third of us are,obese, including 9 million chil...ok like us -- mirror us with similar health issues...partnership that includes,Harvard Medical Center, ...
(Date:7/24/2008)... CosmetaLife clinical trial results could lead ...cost-effective treatment for deep lines and wrinkl...inn. (PRWEB) July 24, 2008 -- Gel-Del Technologie...company announced that it has concluded clinical t...at company officials say holds potential to be a m...
(Date:7/24/2008)...RNewswire-FirstCall/ --, Key Highlights, Misys p...ns and is now,raising targets for the next phase o...) of GBP492m up 6%, bringing Group operating profi...xecuting on its strategy and entering,into the nex...m for growth., To view the Multimedia News Releas...
Breaking Medicine News(10 mins):Health News:PRI: Pro-Life Leader Blames Feminist Groups for Slaughter of Girls 2Health News:PetFit Challenge Helps Keep Pets - and Pet Owners - Healthy 2Health News:Clinical Trial Concluded For New Wrinkle Treatment 2Health News:Clinical Trial Concluded For New Wrinkle Treatment 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 2Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 4
...g blind and partially sighted people in the Lothia...e for the Blind (RNIB) received a ?25,000 donation...help in launching the charity's Positive Steps pro...ning for people preparing to enter employment. Th...
... for Type 2 Diabetes appears to have a twin benefi...ar under control// but also helps them to lose wei...n associate Professor with the Royal Prince Alfred...this drug has been under trial on patient voluntee...
... of teeth, do not improve the mental well being an...study//. Thousands of children have orthodontic wo...n the dental profession that braces or orthodontic...ll-being, reported the online edition of BBC News....
...cer deaths for the second consecutive year, the Am...can Health Challenge// to educate and motivate Ame... Many Americans are concerned about potentially d...t 50 percent of cancer deaths could be prevented t...
Other Medicine News:Health News:Healthy Behaviors Can Prevent at Least 50 Percent of Cancer Deaths 2
(Date:7/23/2008)...Dendreon Corporation,(Nasdaq: DNDN ) today announ...g Committee (IDMC) to review in October 2008 the i...e Company,s Phase 3 IMPACT (IMmunotherapy,for Pros...B) clinical trial,of PROVENGE(R) (sipuleucel-T). P...llular immunotherapy for the treatment of advanced...
(Date:7/22/2008)...t Initiative bring MJFF,s,current active industry ...09, NEW YORK, July 22 /PRNewswire-USNewswire/ -- ...ormative treatments and a cure for Parkinson,s,dis...s Research has awarded,$2.7 million in total fundi... granted under MJFF,s Therapeutics Development Ini...
(Date:7/22/2008)...e to Patients of Passing a Follow-...ly 22 /- Insmed Inc. (Nasda... biopharmaceuticals, today,announced that Geoffrey...ngressional briefing on Friday, July 25th, 2008 to...approval pathway for follow-on,biologics (FOB) and...
(Date:7/22/2008)...re-FirstCall/ -- NicOx S.A.,(Euronext Paris: COX) ...enrollment of 417 osteoarthritis (OA) patients wit...logy studies in the United States, in line with,pr...igned to assess the,blood pressure profile of napr...using the Ambulatory Blood Pressure Monitoring (AB...
Breaking Medicine Technology:Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 1Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 2Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 3Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 4Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 5Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 6Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 7Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 8Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 9Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 10Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 11Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 12Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 13Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 14Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 15Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 16Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 17Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 18Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 19Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 20Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 21Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 22Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 23Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 24Boston Scientific Announces Results for Third Quarter Ended September 30 2007 1366 25AMA 3A NY Attorney General Actions Will Protect Patient Choice of Physicians 4124 1Massive reanalysis of genome data solves case of the lethal genes 1363 1Massive reanalysis of genome data solves case of the lethal genes 1363 2Breast Cancer Survivors and Their Supporters Sing to Live 4121 1Breast Cancer Survivors and Their Supporters Sing to Live 4121 2
... for New Aggrastat Study in American Heart Journal... Inc. (TSX:MPH;,Amex:MCU), a cardiovascular focuse... the two-year, follow-up results from the,STRATEGY...luting,Stent Versus Abciximab and Bare Metal Stent...hed in the July edition of the Journal,of the Amer...
...LD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 r...hat oral dabigatran,etexilate once daily, administ...o enoxaparin, also administered for an average of ...) and all-cause,mortality after total hip replacem...ding associated with dabigatran etexilate was,simi...
Other Medicine Technology:Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 2Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 3Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 4Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 5Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 2Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 3Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 4Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 5
The GENESIS II* Total Knee System will define the state of knee implants.
Cruciate Retaining, Posterior Stabilized and Constrained Components.
StelKast's Proven knee system is a long term, quality solution based on a clinically proven design. Available in both posterior stabilized and anatomically correct cruciate retaining configurations.
The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results.
Medicine Products: